Traders Buy Large Volume of Call Options on Novavax (NASDAQ:NVAX)

Novavax, Inc. (NASDAQ:NVAX) was the recipient of unusually large options trading on Wednesday. Stock traders purchased 24,027 call options on the company. This represents an increase of 99% compared to the average volume of 12,104 call options.

More Novavax News

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Novavax signed a non?exclusive Matrix?M license with Pfizer that pays $30M upfront, up to $500M in development/sales milestones and high mid?single?digit royalties — immediate cash plus sizeable upside if programs succeed. Press Release
• Positive Sentiment: Expanding Matrix?M licensing deals are being viewed as a proof point for a recurring licensing/royalty business model that could boost long?term revenue and valuation upside; some sell?side analysts have reiterated buy ratings on this thesis. TipRanks: Buy Rating Coverage
• Neutral Sentiment: Market commentators and valuation pieces are re?running models to price the new deal into NVAX forecasts; some coverage focuses on how materially the Pfizer license changes discounted cash?flow assumptions. Yahoo Finance: Valuation Assessment
• Neutral Sentiment: Major news outlets (Reuters) confirmed the licensing agreement, which helps cement the development/partnering narrative but does not guarantee milestones will be achieved. Reuters: Deal Coverage
• Negative Sentiment: Bank of America reiterated a Sell rating, arguing execution risk, long?dated cash flows and weak COVID market prospects still undermine profitability — the license reduces but does not eliminate these risks. TipRanks: BofA Sell Note
• Negative Sentiment: Underlying fundamentals remain mixed: recent quarterly results showed revenue declines year?over?year and prior EPS misses; Matrix?M royalties/milestones are contingent on Pfizer program success, so material cash flow depends on future events. Zacks: Deal + Financial Context

Hedge Funds Weigh In On Novavax

A number of institutional investors have recently added to or reduced their stakes in NVAX. Flagship Harbor Advisors LLC purchased a new stake in Novavax during the fourth quarter valued at approximately $33,000. Shah Capital Management raised its position in shares of Novavax by 23.3% during the 4th quarter. Shah Capital Management now owns 14,558,780 shares of the biopharmaceutical company’s stock worth $97,835,000 after purchasing an additional 2,747,000 shares during the last quarter. Stonehage Fleming Financial Services Holdings Ltd purchased a new stake in shares of Novavax during the fourth quarter worth $126,000. SG Americas Securities LLC boosted its stake in Novavax by 6.3% during the fourth quarter. SG Americas Securities LLC now owns 976,388 shares of the biopharmaceutical company’s stock worth $6,561,000 after buying an additional 57,705 shares during the last quarter. Finally, CIBC Bancorp USA Inc. acquired a new position in shares of Novavax in the 3rd quarter valued at $138,000. Institutional investors own 53.04% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on NVAX shares. Cantor Fitzgerald assumed coverage on Novavax in a report on Friday, October 24th. They issued an “overweight” rating and a $18.00 target price on the stock. BTIG Research reaffirmed a “buy” rating and set a $19.00 price objective on shares of Novavax in a research report on Tuesday. HC Wainwright boosted their price target on Novavax from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. Wall Street Zen lowered shares of Novavax from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Novavax in a report on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $11.25.

Novavax Stock Up 9.3%

Shares of NVAX stock traded up $0.76 on Wednesday, hitting $8.96. 7,413,191 shares of the stock were exchanged, compared to its average volume of 5,683,077. Novavax has a fifty-two week low of $5.01 and a fifty-two week high of $10.64. The firm has a market capitalization of $1.46 billion, a P/E ratio of 5.01 and a beta of 2.37. The company has a current ratio of 2.27, a quick ratio of 2.24 and a debt-to-equity ratio of 5.93. The business has a 50-day moving average of $7.01 and a 200 day moving average of $7.67.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.08) by ($0.17). The firm had revenue of $70.45 million during the quarter, compared to the consensus estimate of $55.63 million. Novavax had a net margin of 32.10% and a negative return on equity of 217.02%. The business’s revenue was down 16.7% compared to the same quarter last year. During the same period last year, the business earned ($0.76) earnings per share. Equities analysts anticipate that Novavax will post -1.46 EPS for the current year.

Novavax Company Profile

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.